PROCEPT BioRobotics Corporation

NasdaqGM:PRCT Stock Report

Market Cap: US$4.4b

PROCEPT BioRobotics Management

Management criteria checks 3/4

PROCEPT BioRobotics' CEO is Reza Zadno, appointed in Feb 2020, has a tenure of 4.92 years. total yearly compensation is $6.09M, comprised of 10.1% salary and 89.9% bonuses, including company stock and options. directly owns 0.065% of the company’s shares, worth $2.83M. The average tenure of the management team and the board of directors is 4.9 years and 3.6 years respectively.

Key information

Reza Zadno

Chief executive officer

US$6.1m

Total compensation

CEO salary percentage10.1%
CEO tenure4.9yrs
CEO ownership0.07%
Management average tenure4.9yrs
Board average tenure3.6yrs

Recent management updates

Recent updates

What You Can Learn From PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S

Dec 05
What You Can Learn From PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S

Procept BioRobotics: Continued Growth Runway Ahead

Nov 26

Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

Oct 31
Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

Procept BioRobotics: New Hydros Aquablation System To Fuel Next Leg Of Growth

Sep 12

Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval

Aug 27

Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%

Aug 25
Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%

Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

Aug 04
Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

May 21
PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

Apr 05
The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Mar 01
US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Feb 07
Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Dec 14
Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Feb 27
Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Procept Biorobotics announces $52M debt refinancing

Oct 10

Providence announces national contract for PROCEPT Biorobotics Aquabeam Systems

Sep 19

Procept BioRobotics Has Resources To Ramp Up Commercialization

Sep 01

Procept: Leveraging A Novel Water-Based System For Enlarged Prostate Treatment

May 26

Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

May 10
Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

CEO Compensation Analysis

How has Reza Zadno's remuneration changed compared to PROCEPT BioRobotics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$100m

Jun 30 2024n/an/a

-US$104m

Mar 31 2024n/an/a

-US$103m

Dec 31 2023US$6mUS$613k

-US$106m

Sep 30 2023n/an/a

-US$107m

Jun 30 2023n/an/a

-US$105m

Mar 31 2023n/an/a

-US$98m

Dec 31 2022US$4mUS$575k

-US$87m

Sep 30 2022n/an/a

-US$77m

Jun 30 2022n/an/a

-US$69m

Mar 31 2022n/an/a

-US$64m

Dec 31 2021US$1mUS$490k

-US$60m

Sep 30 2021n/an/a

-US$57m

Jun 30 2021n/an/a

-US$55m

Mar 31 2021n/an/a

-US$53m

Dec 31 2020US$4mUS$435k

-US$53m

Compensation vs Market: Reza's total compensation ($USD6.09M) is about average for companies of similar size in the US market ($USD6.66M).

Compensation vs Earnings: Reza's compensation has increased whilst the company is unprofitable.

CEO

Reza Zadno (69 yo)

4.9yrs

Tenure

US$6,088,813

Compensation

Dr. Reza Zadno, Ph D., has been the President, Chief Executive Officer and Director at Procept Biorobotics Corporation since February 2020. Dr. Zadno served as the Chief Executive Officer at Avedro, Inc. f...

Leadership Team

NamePositionTenureCompensationOwnership
Reza Zadno
President4.9yrsUS$6.09m0.065%
$ 2.8m
Kevin Waters
Executive VP & CFO6.3yrsUS$2.67m0.11%
$ 4.8m
Alaleh Nouri
EVP, Chief Legal Officer & Corporate Secretary6.5yrsUS$2.19m0.031%
$ 1.3m
Hisham Shiblaq
Executive VP & Chief Commercial Officer5.8yrsUS$2.63m0.014%
$ 621.3k
Mohan Sancheti
Senior Vice President of Operationsno datano datano data
Barry Templin
Executive VP of Technology & Clinical Development1.2yrsno datano data
Matthew Bacso
Vice President of Investor Relationsno datano datano data
Stacey Porter
Chief People Officerless than a yearno datano data
Bijesh Chandran
Senior Vice President of Regulatory Affairs & Quality Assurance3yrsno datano data

4.9yrs

Average Tenure

48yo

Average Age

Experienced Management: PRCT's management team is considered experienced (4.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Reza Zadno
President4.9yrsUS$6.09m0.065%
$ 2.8m
Thomas Prescott
Chairperson of the Boardless than a yearno datano data
Frederic Moll
Independent Director13.4yrsUS$277.64k1.49%
$ 65.1m
Taylor Harris
Independent Director4.1yrsUS$254.92k0.24%
$ 10.6m
Larry Wood
Independent Directorless than a yearno datano data
Elisabeth Sandoval-Little
Independent Director3.3yrsUS$242.16k0.015%
$ 644.3k
Mary Garrett
Independent Director3.1yrsUS$244.92k0.017%
$ 742.4k
Antal Desai
Independent Director9.6yrsUS$247.42k0.31%
$ 13.7m
Amy Dodrill
Independent Director3.6yrsUS$252.42k0.0087%
$ 379.5k

3.6yrs

Average Tenure

62yo

Average Age

Experienced Board: PRCT's board of directors are considered experienced (3.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 02:24
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PROCEPT BioRobotics Corporation is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Craig BijouBofA Global Research
Neil ChatterjiB. Riley Securities, Inc.
Michael GormanBTIG